GlassScriptPhysician profile
Reuben Macias
NPI 1174977508
$6,832.84
in general payments reported to CMS, 2019-2025
13 companies · $2,266 in 2025
The $2,266 reported for 2025 was more than what a typical Orthopaedic Surgery provider received nationally (typical 2025 total: $569).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $34.42 · 2021: $641 · 2022: $2,814 · 2023: $171 · 2024: $908 · 2025: $2,266.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,084 · Travel and Lodging: $1,260.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,083.95 |
| Travel and Lodging | $1,260.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alpha Orthopedic Systems | $1,409.22 | 2022-2024 | |
| Stryker Corporation | $1,386.12 | 2021-2024 | Blueprint Patient Specific Instrumentation, Insignia, Mako |
| Smith+Nephew, INC. | $1,292.92 | 2021-2025 | Journey II, Real Intelligence, Legion |
| Rattan and Associates | $1,200.00 | 2022 | |
| Depuy Synthes Sales INC. | $542.84 | 2024-2025 | Attune |
| Zimmer Biomet Holdings, INC. | $538.51 | 2022-2025 | Persona |
| Medical Device Business Services, INC. | $350.33 | 2025 | Velys |
| Orthalign INC | $26.91 | 2023 | Orthalign Plus |
| Terumo Bct, INC. | $23.05 | 2022 | |
| Csl Behring | $23.01 | 2019 | |
| Music City Medical Technologies, LLC | $14.42 | 2024 | |
| Heron Therapeutics, INC. | $14.10 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $11.41 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Reuben Macias listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.